Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China.

ABSTRACT:

Aims

Finerenone has been approved for treating diabetic kidney disease (DKD) with reducing cardiorenal risk. Real-world data on finerenone treatment for the management of DKD are presently lacking. This study aimed to investigate the effect of finerenone on the renal parameters of the Chinese DKD population in the real-world medical setting for the first time, especially in combination with renin-angiotensin system inhibitors (RASi) and sodium-glucose cotransporter 2 inhibitors (SGLT2i).

Methods

Forty-two DKD patients were selected and completed a 6-month finerenone treatment. Renal parameters and adverse effects were collected at every visit.

Results

The median urine albumin-to-creatinine ratio (UACR) was 1426.11 (755.42, 3638.23) mg/g. Among them, the proportion of

SUBMITTER: Zhou J 

PROVIDER: S-EPMC11385639 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature